Navigation Links
NovoCure Ltd. announces closing of financing round
Date:9/28/2009

September 28, 2009 NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures. "We are very pleased that Pfizer, Johnson & Johnson Development Corporation and Index have taken an interest in the work we're doing with the Novo-TTF device," said William Doyle, Chairman of the Board of NovoCure. "The proceeds from their investment will be used to fund NovoCure's newly-diagnosed GBM pivotal clinical trial."

"The NovoCure TTF therapy is a completely novel approach to fighting cancer," said Bill Burkoth, Director of Pfizer Ventures. "Pilot clinical trials suggest that TTF therapy plus chemotherapy has the potential to significantly improve patient survival.

This investment aligns with Pfizer's goal to help oncology patients live longer, healthier lives."

The Novo-TTF device is a unique cancer treatment that uses specially tuned, low intensity electrical fields (Tumor Treating Fields or TTFields) to disrupt cell division. Rapidly dividing cancerous cells are affected by the TTFields , causing them to either break apart or not divide properly, while healthy, non-dividing cells are not affected, yielding a targeted treatment with minimal side effects. The fields are applied to the tumor region using non-invasive, insulated electrodes placed on a patient's skin. The electrodes, which look like bandages, are attached by wires to a battery operated, portable device that generates the fields.

INITIATION OF CLINICAL TRIAL FOR NEWLY DIAGNOSED GBM

The Novo-TTF device has been tested in more than 175 patients with various types of cancers including recurrent and newly-diagnosed glioblastoma multiforme (GBM), breast cancer and lung cancer.

NovoCure recently completed enrollment of a 236-patient, multi-center, randomized Pivotal clinical trial studying the safety and efficacy of the Novo-TTF device treating patients with recurrent GBM compared to standard-of-care chemotherapy. The results of this trial will be presented to the Food and Drug Administration (FDA) as part of a PMA application planned for early next year.

A new, multi-center, Pivotal clinical trial to study the efficacy of the novel Novo-TTF device in combination with standard-of-care chemotherapy (temozolomide) compared to standard-of-care chemotherapy alone in patients with newly-diagnosed GBM is now open in the United States, Europe and Israel. Data from a Pilot study of Novo-TTF in combination with chemotherapy in patients with newly diagnosed GBM suggest that the device may significantly improve upon the standard-of-care when used in combination with chemotherapy. As published in BMC Medical Physics in January of this year, patients treated with TTFields in a Pilot clinical trial for newly diagnosed GBM showed a median time to disease progression of 155 weeks compared to approximately 31weeks for concurrent control patients receiving standard-of-care chemotherapy alone. With 80% still living at the time of publication, the TTF treated patients had not yet reached the median overall survival at 39 months, compared to historical published median overall survival of 14.6 months for newly diagnosed GBM patients receiving standard-of-care chemotherapy alone. The ability to add the Novo-TTF to standard-of-care chemotherapy with minimal additional toxicity makes the treatment particularly attractive. Details about the newly diagnosed GBM trial including trial locations can be found on the NovoCure website (www.novocuretrial.com).


'/>"/>

Contact: Jennifer Paganelli Schwartz
jennifer.schwartz@edelman.com
212-642-7774
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. NovoCure presents results from breast cancer pilot study
2. RCRC Independent Review Board Announces DHHS Research Oversight
3. change:healthcare Announces Twitter Application that brings Healthcare Information and Costs to Consumers' Fingertips
4. QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
5. I-Therapeutix, Inc. Announces Company Name Change
6. President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
8. US Farms, Inc. Announces Broker Network Agreement With Sunshine Specialties for Aloe365 Products
9. ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
10. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
11. Strategic Information Group Announces QAD Enterprise Validation Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 ... alone responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To ... 1512, which proposes a tax on prescription opioids to fund drug rehabilitation and ...
(Date:3/25/2017)... ... 25, 2017 , ... Getting earned media coverage meaningful for Garden Media Group's ... through the year, Garden Media aims to provide material helpful to clients’ goals and ... pitching client’s key messages to gain coveted media placements, Garden Media wows clients ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces distribution of ... current obstacles facing infection prevention and offer strategies for the health care community ... , The print component of “Fighting Infection” is distributed within the Friday, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company ... in children, today reported financial results for the ... 2016 and provided an update on its corporate ... progress during the fourth quarter of 2016 through ... safety study, and with our lead development candidate, ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets ... Market, 2017-2027" report to their offering. ... The Cell Therapy Manufacturing ... growing market of cell therapy manufacturing and focuses both on ... These therapies are anticipated to emerge as viable alternatives to ...
(Date:3/24/2017)... March 24, 2017  Zymo Research Corp., ... Hamilton Robotics, Inc., who designs, manufactures and ... collaboration that teams Zymo Research,s DNA methylation ... DNA extraction products with Hamilton,s high-throughput automation ... methods for microbiomics and RNA isolation for ...
Breaking Medicine Technology: